Bausch-lomb Incorporated

Other

Bausch + Lomb Ireland Limited

Erning Xia

Susan E Burke

Srini Venkatesh

Kimberly Anne Millard

Vicki Barniak

Richard V Smerbeck

John Denick

Praveen Tyle

Lisa C Simpson

Ruth Julian

Catherine A Scheuer

Joseph C Salamone

Alok Kumar Awasthi

David J Heiler

Suzanne F Groemminger

Jennah L Wolcott

Pramod Kumar Gupta

Susan E Norton

Krista Fridman

Lynne Brunner

Alyce K Dobie

Jenilee Kilbury

Michael E Allen

Keith W Ward

Craig Michael Cody

Daniel M Ammon, Jr

Dharmendra M Jani

Madhu S Ayyagari

Craig M Cody

Zhenze Hu

X Michael Liu

Hongna Wang

Roya Nicole Borazjani

William T Reindel

Susan P Spooner

Daniel J Hook

Stephen E Maier

Jill S Rogalskyj

Xiaojun Michael Liu

Catherine Scheuer

Steven K MacLeod

Srini Venkastesh

Tammy J Kleiber

Deborah McGrath

Christine E Soltys-Robitaille

Rebecca Franklin

David J McCanna

Bill Reindel

Honga Wang

Vicki L Barniak

Steven K Macleod

Daniel M Ammon

Matthew Scott Jonasse

Kimberly L Millard

Paul T Lavoie

Roya N Borazjani

A viscoelastic composition is disclosed which comprises (a) tris(hydroxymethyl)aminomethane or a salt thereof; (b) a phosphate buffer agent; and (c) a viscoelastic agent having an average molecular weight of about 100 to about 5,000,000.

Ophthalmic viscoelastic compositions

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Packaging solutions

A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9.

Ophthalmic device packaging solutions comprising tris(hydroxymethyl)aminomethane and nonionic surfactant

Ophthalmic device packaging solutions comprising a poloxamine/erythritol mixture

The invention is directed to a method of cleaning and disinfecting a contact lens. The method includes instructing a consumer to disinfect their contact lens comprising the following steps: remove a contact from an eye and position the lens in a lens assembly that includes a cap member; add a disinfection solution to the lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member. The disinfection solution will comprise 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfection solution decreases the neutralization rate of the hydrogen peroxide. The disinfection system exhibits a pseudo first-order, half-life of hydrogen peroxide from 12 minutes to 30 minutes over an initial sixty minutes of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal. This reduction in rate of peroxide neutralization can provide a more effective solution for killing certain microorganisms and fungi.

Peroxide contact lens care solution

A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses.

Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide

Ophthalmic compositions comprising 0.005 wt. % to 2.0 wt. % of alkoxylated natural waxes selected from the group consisting of alkoxylated lanolin and alkoxylated jojoba, and a method of treating a patient diagnosed with dry eye syndrome, or for cleaning and disinfecting contact lenses, with the ophthalmic compositions.

Ophthalmic compositions with alkoxylated natural waxes

A poly(nitrogen/amine) derivative of a natural wax of formula I, and ophthalmic compositions and contact lens care solutions that contain the poly(nitrogen/amine) derivative of a natural wax of formula I. The invention is also directed to a method of treating a patient with dry eyes, the method comprising instructing a patient to administer one or more eye drops of the ophthalmic composition that includes a poly(nitrogen/amine) derivative of a natural wax of formula I.

Poly(nitrogen/amine) derivatives of a natural wax and ophthalmic compositions

Ophthalmic compositions that comprise 0.1 ppm to 50 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 2 wt. % of an anionic biopolymer; and 0.01 wt. % to 2 wt. % of an amphoteric surfactant of general formula I 

Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer

A contact lens disinfecting solution that comprises 0.5 wt. % to 6 wt. % hydrogen peroxide, or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfecting hydrogen peroxide solution slows the rate at which the hydrogen peroxide is neutralized, particularly during the initial two hours, by a catalyst element that includes a P-metal. This reduction in rate of peroxide neutralization provides a more effective solution for killing certain microorganisms and fungi.

Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm &#x3b1;-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-&#x3c9;-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Ophthalmic compositions containing diglycine

Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections.

Compositions and methods for treating, reducing, ameliorating, or preventing infections

Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 1.0 ppm to 8.5 ppm alexidine, and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.

Growing community of inventors

Penfield, NY, United States of America

Erning Xia